Summit Therapeutics’ stock surges as lung-cancer treatment vies with Merck’s blockbuster

Shares of Summit Therapeutics jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck’s blockbuster Keytruda in a late-stage trial.

For more details: Read More